The Market Is Nervous. This Growth Stock Is Your Shot at Doubling Up.

Chewy ended fiscal 2025 with 21.3 million active customers, up 4%, while Autoship sales rose 11.8% year over year to $10.5 billion and accounted for 83.3% of sales. Management is expanding into healthcare, including 18 clinics after adding 10 last year, and plans to acquire Modern Animal for 29 more clinics and $125 million in annual sales. The stock is down 21.6% this year and trades at 52x earnings, which the article frames as an attractive long-term entry point despite the valuation.

Analysis

CHWY is a classic quality-vs-price dislocation: the market is discounting a slowdown in discretionary spend, but the business mix is quietly shifting toward higher-retention, higher-frequency categories that are less exposed to transactionality. The more important second-order effect is that Autoship and healthcare deepen switching costs, which should support LTV/CAC even if top-line growth normalizes; that makes the stock less about near-term revenue acceleration and more about sustained gross profit compounding over multiple years.

The competitive implication is that CHWY is not just taking share from pet retail, but increasingly from fragmented local veterinary and pharmacy channels. If the clinic rollout and Modern Animal integration work, the company can use the customer relationship to pull more wallet share into services where incumbents have weaker digital infrastructure and lower convenience. That could also pressure smaller pet-health platforms and local clinics on pricing and retention, especially if CHWY subsidizes service adoption to lock in repeat prescription and appointment behavior.

The risk is that the stock is still being valued like a premium growth compounder while the near-term proof point is only mid-single-digit customer growth. If macro worsens, the first reflexive multiple compression can easily outrun any fundamental resilience, and healthcare expansion has execution risk because clinics are capital intensive and slower to scale than e-commerce. The contrarian setup is that consensus is likely underestimating how defensive pet spend is relative to broader consumer discretionary, so the downside in sales may be smaller than feared even if sentiment remains weak for 1-2 quarters.

Key Decisions for Investors

• Start a 6-9 month tactical long in CHWY on further weakness; target a re-rating if the market begins to price the healthcare mix shift as recurring revenue rather than optionality. Risk/reward improves materially if the stock de-risks into the low-40s on continued multiple compression.
• Pair long CHWY / short a basket of higher-beta discretionary names that are more exposed to trade-down and impulse spending pressure. The thesis is relative defensiveness plus internal monetization, with the short leg hedging macro sentiment risk over the next 1-2 quarters.
• Avoid chasing size into the current move higher; wait for either a post-earnings drawdown or a market-wide risk-off tape to establish exposure. The cleanest entry is when volatility expands and the market is pricing recessionary demand destruction ahead of actual customer churn.
• For options, consider a 6-12 month call spread in CHWY rather than outright stock to cap valuation risk. The structure fits a slow-burn thesis where the catalyst is mix improvement and multiple stabilization, not immediate upside surprise.
• Monitor clinic economics and integration milestones closely; if management shows that healthcare contribution can scale without margin dilution, add on confirmation. If clinic rollout starts to pressure operating leverage, cut quickly because the market will punish any sign that growth is becoming capital inefficient.